Division of Patheon Inc./Banner Pharmacaps Inc.
Latest From Patheon Inc.
More M&A may be in store in the contract development and manufacturing space, with the founder of India’s Strides group apparently open to divesting his holding in the UK-based Sterling Pharma Solutions, at least going by what some deal street insiders say.
The contract drug delivery industry is facing disruptive influences from an evolving client base, the increase in biologics manufacturing and specialty pharma needs. In Vivo speaks to Catalent’s vice president of strategy, Cornell Stamoran, about the evolution of the industry and the continuous search for efficiency.
Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.
It's time for In Vivo's 10th annual Deal of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Patheon NV
- Patheon Holdings Cooperatief UA
- North America
- Parent & Subsidiaries
- Patheon Inc.
- Thermo Fisher Scientific Inc.
- Senior Management
James C Mullen, CEO
Stuart Grant, EVP, CFO
Michael Lehmann, Pres. Global Sales & Marketing
Eric M Sherbert, General Counsel & Secretary
Rebecca N Holland, Corporate Officer, EVP, Enterprise-wide Ops
Franco Negron, SVP CMO North America
Harry Gill, Sr VP, Quality & Operational Excellence
Ray Guidotti, SVP, Global Capacity Planning & Engineering
Michel Lagarde, Pres.
Michael Lytton, EVP, Corp Dev & Strategy
Lukas Utiger, Pres, Drug Substance
Gilles Cottier, Pres, Pharma Dev Services
- Contact Info
Phone: (919) 226-3200
4815 Emperor Blvd.
Durham, NC 27703-8580